SEATTLE and SOUTH SAN FRANCISCO, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced it will host a post-ASCO Clinical Research Update on Tuesday, June 2, 2015 at 5:30 p.m. Eastern in New York to review the three Phase 1 data sets presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
The three trials provide first-in-human clinical data with the company's immuno-oncology cancer agents that are designed to generate anti-tumor immunity. These studies are the foundation of the company's two primary product candidates, CMB305 and G100. Participants will include principal investigators from ASCO-selected posters and poster discussion as well as Immune Design senior leadership.
A live webcast of the event will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website.
Investors and analysts who would like to attend the event in New York, at the Grand Hyatt Hotel, should contact Jennifer Cortes, at email@example.com or +1 650 887 6703.
Presentations at the event will include:
"Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1."
ASCO presenter Neeta Somaiah, M.D. Assistant Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
"A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1."
ASCO presenter Amit Mahipal, M.D., Medical Director, Clinical Research Unit; Assistant Member, Department of GI Oncology, Moffitt Cancer Center, Tampa, FL
"Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC)."
Frank Hsu, M.D. Vice President, Head of Oncology, Immune Design
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.